SCHEMBL9892679

SCHEMBL9892679

CNC(=O)Cc1cc(C(F)(F)F)ccc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.47
TACR1 P25103 7/20 0.45
BACE1 P56817 1/20 0.45
PLK1 P53350 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
FABP4 P15090 2/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
ALDH1A1 P00352 1/20 0.42
FABP5 Q01469 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9892662 0.89 PTGDR2 (0.50) PTGDR2TACR1BACE1PLK1PSEN1
SCHEMBL9892693 0.87 PTGDR2 (0.48) PTGDR2TACR1PSEN1PSEN2APH1B
SCHEMBL9892653 0.84 PSEN1 (0.56) PTGDR2TACR1BACE1PSEN1PSEN2
SCHEMBL2395131 0.83 KCNJ5 (0.49) TACR1BACE1PSEN1PSEN2APH1B
SCHEMBL9890777 0.83 PSEN1 (0.46) BACE1PSEN1PSEN2APH1BNCSTN
SCHEMBL2393347 0.83 RORC (0.48) TACR1BACE1ALDH1A1MEN1MAPT
SCHEMBL2396004 0.82 FFAR1 (0.46) PTGDR2ALDH1A1MAPT
SCHEMBL9892691 0.82 PTGDR2 (0.50) PTGDR2TACR1BACE1PSEN1PSEN2
SCHEMBL9890782 0.82 PSEN1 (0.45) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9890763 0.80 HDAC7 (0.47) PTGDR2ALDH1A1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885TACR1 2276/4885BACE1 2072/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885TACR1 2276/4885BACE1 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.